Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.

NCT07319897 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.

NCT NCT07319897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07319897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.
Lead sponsor
Peking University First Hospital
Phase
Phase 2/3
Overall status
Recruiting
Start date
December 25, 2025
Completion date
December 30, 2027
Enrollment
300 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, multiple myeloma and malignant plasma cell neoplasms, multiple myeloma and plasma cell neoplasm